The overexpression of transferrin receptor 1 (TfR1) has been reported in several cancer types but is also expressed in normal cell types such as erythroblasts. On the other hand, epidermal growth factor receptor (EGFR) is highly expressed in epithelial carcinomas.
Cereno Scientific AB has submitted a clinical trial application (CTA) to the EMA seeking approval for a first-in-human, phase I study of CS-014, a novel histone deacetylase (HDAC) inhibitor drug candidate under development as an antithrombotic treatment.
Sitryx Therapeutics Ltd. has nominated SYX-5219 as the first candidate from its proprietary pipeline to progress to regulatory nonclinical studies to support a clinical trial authorization (CTA). SYX-5219 has the potential to address a broad range of inflammatory diseases and will advance into the clinic for the treatment of atopic dermatitis.
A team from GC Cell Corp. reported preclinical data on GL-205, a novel allogeneic anti-CD5 CAR-NK being developed for the treatment of T-cell malignancies. GL-205 was developed using cord blood-derived NK cells that were genetically modified to express CD5-directed CAR and simultaneously produce IL-15 to support NK cell survival and proliferation.
Wound healing is a highly specialized dynamic process for the repair of damaged/injured tissues through an intricate mechanism. Any failure in the normal wound healing process results in abnormal scar formation, and a chronic state which is more susceptible to infections. Researchers from Monash University in Australia and Osaka University in Japan have demonstrated that the removal of a specific subtype of sensory neurons containing the Nav1.8+ ion channel significantly impairs skin wound repair and muscle regeneration following injury.
Cerevel Therapeutics LLC has described muscarinic M4 receptor agonists reported to be useful for the treatment of pain, sleep disorder, schizophrenia, substance abuse and dependence, drug-induced dyskinesia, Alzheimer’s disease and Parkinson’s disease.
Simcere Zaiming Pharmaceutical Co. Ltd. has divulged proteolysis targeting chimera (PROTAC) compounds comprising a cereblon E3 ubiquitin ligase binding moiety coupled to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or bromodomain-containing protein 4 (BRD4; HUNK1) targeting moiety through a linker reported to be useful for the treatment of cancer.
Scientists at Ez Bioxcel Solutions Pvt Ltd., Invea Therapeutics Inc. and Inveniai LLC have identified apoptosis-associated speck-like protein containing a CARD (PYCARD; ASC) inhibitors reported to be useful for the treatment of primary sclerosing cholangitis, arthritis and inflammatory disorders.
Recurium IP Holdings LLC has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) binding moiety covalently linked to a Wee1-like protein kinase (Wee1)-targeting moiety via a linker reported to be useful for the treatment of cancer.
Vanderbilt University has disclosed mGlu5 receptor negative allosteric modulators reported to be useful for the treatment of anxiety, autism spectrum disorders, diabetes, pain, Parkinson’s disease, multiple sclerosis, depression and obesity, among others.
RSS
